-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

An Expert Guide to What's New and What''s Next for Novel Targeted Therapies in Relapsed/Refractory Follicular Lymphoma

Sponsor: educational grants from Genentech, a member of the Roche Group; Genmab, Ipsen Biopharmaceuticals, Inc, and Regeneron Pharmaceuticals, Inc. Provided by Clinical Care Options, LLC.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Diseases, Therapies
Friday, December 8, 2023: 3:00 PM-6:00 PM
Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)
Julie M. Vose, MD, MBA, University of Nebraska Medical Center
Vose: Eli Lilly and Company; Epizyme, Kite, Loxo, Novartis: Research Funding; AbbVie, MEI Pharma: Consultancy.
Sonali M. Smith, University of Chicago and Peter Martin, MD, Weill Cornell Medical College
Smith: Bristol-Myers Squibb, Gilead, Ono Pharmaceutical: Consultancy, Speakers Bureau. Martin: AbbVie, AstraZeneca, Beigene, Epizyme, Genentech, Gilead, Janssen, Pepromene, Daiichi Sankyo: Consultancy.
This dynamic symposium will combine engaging presentations and case-oriented panel discussions, showcasing expert opinions and treatment advice for relapsed/refractory (R/R) Follicular Lymphoma (FL). Directly engage with the expert panelists during the "Live Case and Question Submission" sessions during which you can present your questions and real-world cases to our experienced faculty for customized guidance. The symposium will navigate the current landscape of R/R FL treatment, unpack ground-breaking clinical research, and project future strategies into 2024. This experience promises to enrich your understanding of R/R FL, challenge your clinical acumen, and empower you to implement the latest knowledge in your practice. We invite you to contribute to this thought-provoking dialogue on R/R FL, shaping the discourse and contributing to the collective understanding of this critical area.